Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a b
3 Spectacular High-Yield Dividend Stocks to Buy in November
09:30am, Sunday, 10'th Nov 2024
High yields aren't a warning indicator with these three stocks.
Gilead Sciences: Finally Some Real Momentum
04:44pm, Friday, 08'th Nov 2024
Shares of Gilead Sciences, Inc. experienced a downturn early in 2024 due to pipeline setbacks and underwhelming guidance, but shares have seen a significant recovery recently. The company's reliance o
Gilead Sciences to Present at Upcoming Investor Engagements
04:05pm, Friday, 08'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthca
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
01:46pm, Thursday, 07'th Nov 2024
Gilead Sciences Inc GILD stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its fiscal year 2024 guidance.
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
12:15pm, Thursday, 07'th Nov 2024
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
Gilead's Stock Surge: What's Fueling the Momentum?
12:09pm, Thursday, 07'th Nov 2024
Gilead Sciences NASDAQ: GILD recently broke its 52-week high and is up over 40% over the past six months. As a leading biopharmaceutical company dedicated to pioneering innovative therapies, Gilead bo
Gilead Sciences Tops Estimates in Q3
11:44am, Thursday, 07'th Nov 2024
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
08:40am, Thursday, 07'th Nov 2024
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio and increased demand for COVID-19 therapy Veklury. Oncology remains a weak area, with CAR-T
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infec
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
08:58pm, Wednesday, 06'th Nov 2024
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Markets Tear Off the Lid in Hump-Day Trading
07:10pm, Wednesday, 06'th Nov 2024
A decisive win for Donald Trump and the Republican Party in both the White House and Congress will likely usher in very aggressive pro-business policies.
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
07:00pm, Wednesday, 06'th Nov 2024
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
06:21pm, Wednesday, 06'th Nov 2024
Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago.
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance
04:36pm, Wednesday, 06'th Nov 2024
Gilead Sciences Inc.'s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19
